18 assets in Diastolic Heart Failure

Therapeutic assets addressing Diastolic Heart Failure, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Metformin Diastolic Heart Failure	Sara ElAdawy	P4	BBB (74)
Semaglutide Diastolic Heart Failure	Mayo Clinic	P4	BBB (74)
Tirzepatide Diastolic Heart Failure	Yunlong Wang	P4	BBB (74)
Tadalafil Diastolic Heart Failure	Kafrelsheikh University	P4	BB (65)
Pioglitazone Diastolic Heart Failure	The University of Texas Health Science Center at San Antonio	P4	BB (64)
Maridebart Cafraglutide Diastolic Heart Failure	Amgen	P3	B (60)
Gadoterate Diastolic Heart Failure	IC TARGETS AS	P2	B (57)
hu6 Diastolic Heart Failure	Rivus Pharmaceuticals, Inc.	P2	B (57)
Mangafodipir Trisodium Diastolic Heart Failure	IC TARGETS AS	P2	B (57)
hrs9531 Diastolic Heart Failure	Fujian Shengdi Pharmaceutical Co., Ltd.	P2	CCC (53)
Mazdutide Diastolic Heart Failure	Innovent Biologics (Suzhou) Co. Ltd.	P2	CCC (53)
hs135 Diastolic Heart Failure	35Pharma Inc	P1	CC (43)
hs235 Diastolic Heart Failure	35Pharma Inc	P1	CC (43)
AIR Diastolic Heart Failure	University of Texas Southwestern Medical Center	N/A	D (30)
Carvedilol Diastolic Heart Failure	Post Graduate Institute of Medical Education and Research, Chandigarh	N/A	D (30)
Dapagliflozin Diastolic Heart Failure	National Medical Research Center for Cardiology, Ministry of Health of Russian Federation	N/A	D (30)
Rifaximin Diastolic Heart Failure	I.M. Sechenov First Moscow State Medical University	N/A	D (30)
Simvastatin Diastolic Heart Failure	Post Graduate Institute of Medical Education and Research, Chandigarh	N/A	D (30)